Cardiology

Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session

Retrieved on: 
Monday, March 25, 2024
Cardiology, Pharmacology, Internal medicine, Safety, Associate, SAN, Cytokinetics, University, Patient, American College, Cardiomyopathy, Heart failure, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations at the American College of Cardiology 73rd Annual Scientific Session (ACC.24) taking place in Atlanta, GA from April 6, 2024 – April 8, 2024.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations at the American College of Cardiology 73rd Annual Scientific Session (ACC.24) taking place in Atlanta, GA from April 6, 2024 – April 8, 2024.
  • Title: 1075-11 - Efficacy and Safety of Aficamten in the First Cohort of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy Completing 1-Year Follow-Up: Findings From the FOREST-HCM Study
    Presenter: Sara Saberi, M.D., M.S., Associate Professor of Internal Medicine, University of Michigan Health Frankel Cardiovascular Center
    Session: 1226 - Heart Failure and Cardiomyopathies: Special Populations 02
    Session: 1343 - Heart Failure and Cardiomyopathies: Pharmacology 08

Gedeon Richter Selects Trial Interactive for Clinical Trial Management

Retrieved on: 
Monday, March 25, 2024
Biotechnology, Cardiology, Health, Diabetes, Gedeon Richter, CNS, Rheumatology, Trial, Life, Neuropsychiatry, CFR, TMF, Osteoporosis, Blood, Pharmaceutical industry

The Trial Interactive eClinical platform was designed by clinical professionals for clinical professionals.

Key Points: 
  • The Trial Interactive eClinical platform was designed by clinical professionals for clinical professionals.
  • The Trial Interactive platform comprises clinical research-focused products that simplify tasks, oversight, compliance, and audits/inspections.
  • “The Trial Interactive eTMF will help us streamline our TMF operations and maintain inspection readiness.
  • Trial Interactive Division President Michael Smyth commented, “We’re proud to be part of Gedeon Richter’s plans for new studies and look forward to working more closely with their clinical operations teams through our TMF services.”

Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer

Retrieved on: 
Monday, March 18, 2024
Neurology, University of Pennsylvania, Sarcoma, Cardiology, Ivy League, Protocol, University, Rheumatology, Dermatology, Infection, Harvard University, FSD, Melanoma, CMO, Vaccine, FDA, GU, Women's health, Yale University, Pharmaceutical industry

MALVERN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Dr. Huma Qamar as Chief Medical Officer (CMO).

Key Points: 
  • MALVERN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Dr. Huma Qamar as Chief Medical Officer (CMO).
  • “I’m very pleased to name Dr. Qamar as the CMO at Ocugen,” said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen.
  • Her expertise encompasses the development of Phase I-IV clinical protocols and execution of clinical studies, FDA inspections, and effective leadership of medical affairs teams.
  • “Dr.

FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population

Retrieved on: 
Thursday, March 14, 2024
Organization, Obesity, Cirrhosis, Exercise, Cardiology, Partnership, F2, Risk, Patient, Fatty liver disease, Hope, Diet, NASH, Language, Liver disease, Liver cancer, Hypertension, FDA, Drug development, JD, Food, GLI

Developed by Madrigal Pharmaceuticals, Rezdiffra™ (resmetirom) was approved for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis, in conjunction with diet and exercise.

Key Points: 
  • Developed by Madrigal Pharmaceuticals, Rezdiffra™ (resmetirom) was approved for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis, in conjunction with diet and exercise.
  • This breakthrough follows years of NASH patient-led, multi-stakeholder advocacy and partnership with researchers in both drug and diagnostic development.
  • “Today’s announcement represents the culmination of the work of the united NASH community.
  • It is particularly satisfying that we can mark Women’s History Month with a breakthrough from a female-founded company.

HeartSciences Reports Third Quarter Fiscal 2024 Financial Results

Retrieved on: 
Thursday, March 14, 2024
Diabetes, Health, HSCS, Algorithm, Intelligence, Patient, Acquisition, Death, Cardiology, Completeness, Patent, Cardiovascular disease, FDA, Regulation, Police, Medical device

Southlake, TX, March 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the third quarter fiscal 2024 ended January 31, 2024 and provided a business update.

Key Points: 
  • Southlake, TX, March 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the third quarter fiscal 2024 ended January 31, 2024 and provided a business update.
  • HeartSciences has seen a fundamental change in its business opportunity since the end of the second fiscal quarter, with material improvements to its financial position and outlook.
  • During the third quarter fiscal 2024, the Company raised $9.2 million in net proceeds from sales of common stock and converted $1.1 million of debt to equity.
  • Complete financial results have been filed in the Company’s quarterly report on Form 10-Q with Securities Exchange Commission and is available on the Company’s website.

Royal Farms Demonstrates Commitment to Community with $150,000 Donation to Johns Hopkins Children's Center

Retrieved on: 
Wednesday, March 13, 2024
Royal Farms, Health, Coin, Organization, Johns Hopkins Children's Center, Neurology, Cardiology, Partnership, Patient, Farm, Hope, Operation, Neonatology, Hospital

BALTIMORE, March 13, 2024 (GLOBE NEWSWIRE) -- Royal Farms, a leading convenience store chain known for its commitment to serving communities, proudly announces a generous donation of $150,000 to the Johns Hopkins Children's Center.

Key Points: 
  • BALTIMORE, March 13, 2024 (GLOBE NEWSWIRE) -- Royal Farms, a leading convenience store chain known for its commitment to serving communities, proudly announces a generous donation of $150,000 to the Johns Hopkins Children's Center.
  • Since 1994, Royal Farms has collected over $3 million in coins from spare change donated from customers and provided it to Johns Hopkins Children’s Center to show our dedication to supporting children's health and well-being in the community.
  • "Royal Farms is honored to support the incredible work being done at Johns Hopkins Children's Center," said Jeff Mengel, Vice President of Operations at Royal Farms.
  • "We are incredibly grateful for Royal Farms' generous donation and ongoing support," said Jennifer Phelps at Johns Hopkins Children's Center.

Wayne J. Franklin, M.D., F.A.C.C., named senior vice president of the Children’s National Heart Center

Retrieved on: 
Wednesday, March 13, 2024
Internal medicine, Obstetrics, Ventricular septal defect, Gynaecology, Cardiology, Pediatric nursing, Education, Pulmonary hypertension, Patient, Duke University, SVP, Research, Electrophysiology, University, Pregnancy, Quality, Pediatrics, Hospital, Safety, Division, Children's National Hospital, Baylor University, Williams College

Washington, D.C., March 13, 2024 (GLOBE NEWSWIRE) -- Children's National Hospital has appointed Wayne J. Franklin, M.D., F.A.C.C., as the new senior vice president (SVP) of the Children’s National Heart Center .

Key Points: 
  • Washington, D.C., March 13, 2024 (GLOBE NEWSWIRE) -- Children's National Hospital has appointed Wayne J. Franklin, M.D., F.A.C.C., as the new senior vice president (SVP) of the Children’s National Heart Center .
  • Dr. Franklin currently serves as co-director, medical director of Quality and endowed chair in the Center for Heart Care and associate director of the Adult Congenital Heart Disease Program at Phoenix Children’s.
  • “I look forward to leading the exceptional Heart Center team at Children’s National, as we contribute to advancing pediatric cardiac care and research,” said Dr. Franklin.
  • “Together with our Heart Center leadership team, he will ensure we’re meeting the highest standards of safety, quality and innovative care for our patients and families.”
    The Children’s National Heart Center is a multidisciplinary center that provides high-quality and innovative pediatric cardiac care.

NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD

Retrieved on: 
Tuesday, March 12, 2024
Consensus, Moyamoya disease, Cardiovascular disease, Myocardial infarction, Dyslipidemia, CVD, Cardiology, Risk, Patient, Apolipoprotein B, Consensus decision-making, Stroke, NAMS, ASCVD, Plaque, Artery, Diet, Cleveland Clinic, Ezetimibe, Clinical trial, Safety, FDC, Apolipoprotein, Genetic disorder, Physician, Pharmaceutical industry

NAARDEN, The Netherlands and MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the dosing of the first patient and initiation of TANDEM, a pivotal Phase 3 clinical trial to evaluate obicetrapib and ezetimibe FDC in adult patients with Heterozygous Familial Hypercholesterolemia (“HeFH”) and/or Atherosclerotic Cardiovascular Disease (“ASCVD”) or multiple risk factors for ASCVD, whose LDL-C is not adequately controlled despite being on maximally tolerated lipid-modifying therapies.

Key Points: 
  • The ACC Expert Consensus set LDL-C goals of below the 70mg/dl for patients with ASCVD and below the 55mg/dl goal for ASCVD patients with very high risk.
  • The primary objective of the placebo-controlled, double-blind, four-arm, randomized TANDEM trial is to evaluate the effect of 10mg obicetrapib and 10mg ezetimibe FDC on LDL-C levels, compared to both ezetimibe 10mg and obicetrapib 10mg monotherapy and to placebo.
  • NewAmsterdam anticipates enrolling approximately 400 patients on maximally tolerated lipid-modifying therapies with HeFH, ASCVD or ASCVD risk equivalents and who have a baseline LDL-C of at least 70 mg/Dl.
  • Patients who have multiple risk factors for ASCVD are at high risk of experiencing a cardiovascular event in the near future.

egnite, Inc. and JenaValve Announce Novel Research on Outcomes with Untreated Aortic Regurgitation at the 2024 American College of Cardiology Conference

Retrieved on: 
Saturday, April 6, 2024
Research, Technology, Medical Devices, Health Technology, Cardiology, Software, Health, Data Management, Science, Artificial Intelligence, Aortic stenosis, Aortic regurgitation, Patient, Mortality, MD, American College, TAVR, Multimedia, Teaching

egnite, Inc. , a leading digital health company for cardiovascular care, and JenaValve Technology, Inc. , a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, unveil a novel study presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.24).

Key Points: 
  • egnite, Inc. , a leading digital health company for cardiovascular care, and JenaValve Technology, Inc. , a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, unveil a novel study presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.24).
  • This press release features multimedia.
  • “This research underscores the poor outcomes for patients with moderate AR who exhibit cardiac damage, stressing the need to monitor distinct characteristics in this population.
  • Recent conservative estimates suggest that over 500,000 patients in the United States are diagnosed with moderate or severe AR, indicating a substantial opportunity for novel therapeutic options to treat patients suffering from AR.

Cardiawave is presenting the 30-day follow-up results from its “Valvosoft® Pivotal Study” on the treatment of severe symptomatic aortic valve stenosis

Retrieved on: 
Friday, April 5, 2024
Medical Devices, Health, Clinical Trials, Radiology, Cardiology, Biotechnology, Science, FIM, Patient, Journal, Research, Quality of life, American College, Calendar

Cardiawave SA, a French medtech company that has developed an innovative Non-Invasive focused Ultrasound Therapy (NIUT) device for the treatment of severe symptomatic calcific aortic stenosis, will present the 30-day follow-up results for 60 patients enrolled in its European pivotal study to the 73rd annual conference of the American College of Cardiology in Atlanta, Georgia.

Key Points: 
  • Cardiawave SA, a French medtech company that has developed an innovative Non-Invasive focused Ultrasound Therapy (NIUT) device for the treatment of severe symptomatic calcific aortic stenosis, will present the 30-day follow-up results for 60 patients enrolled in its European pivotal study to the 73rd annual conference of the American College of Cardiology in Atlanta, Georgia.
  • This is a leading event in the cardiovascular medicine calendar, which brings together specialists from around the world to discuss the latest advances, research results and clinical innovations in the field of cardiology.
  • Prof. Eric Van Belle, cardiologist at Lille University Hospital, one of the principal investigators for the European pivotal study, commented: “I’m very proud to present the excellent results obtained using Cardiawave’s NIUT device to treat patients with severe symptomatic aortic valve stenosis, leading to a significant improvement in their condition and a better quality of life.
  • Time and date: April 8, 2024 - 9:32 a.m.–9:42 a.m. EDT
    The results of the Cardiawave First-in-Human “Valvosoft® FIM Study” were published in The Lancet in November 2023: